Ann: Security Class Reinstatement to Quotation- OPTOB, page-551

I definitely think the market is missing this bit substantially, wet-AMD is one of the most lucrative drug markets in the world. When patents still fully covered them the leading anti-VEGF drug was within the top 5 drugs by sales. OPT will enable one of these lucky players to retain this patent protection and continue racking in billions of dollars each year, not to mention offer enhanced treatment thanks to improved efficacy and improved VA. In its own OPT should command a valuation well in excess of $10 billion on account of the substantial cash flows likely to be generated from this treatment (which doesn’t need to compete with existing treatments for its a combo procedure), to one of the larger players however they’d likely be willing to pay well in excess of that.